Home / Business and Economy / Dr Lal PathLabs Buys Genomics Stake for ₹168 Cr

Dr Lal PathLabs Buys Genomics Stake for ₹168 Cr

24 Sep

Summary

Dr Lal PathLabs acquired a 70% stake in SN Genelab for up to ₹168 crore.
The deal includes a performance-linked earn-out capped at ₹31.5 crore.
SN Genelab operates in the diagnostics-genomics industry, founded in 2013.

Dr Lal PathLabs announced on September 24, 2026, its approval to acquire a 70% stake in SN Genelab Private Ltd for a cash sum of up to ₹168 crore. The acquisition also includes a performance-linked earn-out potentially reaching ₹31.5 crore. This move positions SN Gene as a subsidiary of Dr Lal PathLabs.

The transaction is scheduled for completion by November 30, 2026. SN Gene, established in Gujarat in 2013, specializes in genomics diagnostic services. Its turnover was ₹57.96 crore in FY26, showing growth from previous years.

The primary objective for Dr Lal PathLabs is to deepen its capabilities in genomics and diversify its advanced diagnostic services. This acquisition is funded through cash and is not considered a related party transaction, requiring no governmental or regulatory approvals.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.